Peppermint Oil
Summary
Peppermint oil is the best-studied herbal option for irritable bowel syndrome. Pooled trials, most recently a 2022 meta-analysis of 10 RCTs, favour it over placebo (grade B), but the two most rigorous recent trials missed their main goals, and evidence quality is very low. Heartburn is the usual side effect, which enteric coating aims to reduce.
Key facts
- Global IBS symptoms: better than placebo across 10 RCTs and 1,030 patients (RR of not improving 0.65), with very low evidence quality (B)[5]
- The 189-patient PERSUADE trial missed both primary endpoints, and a 133-patient US trial found no difference from placebo[2][4][8]
- Heartburn, nausea, abdominal pain and dry mouth; adverse events were more common than with placebo (RR 1.57)[1][5]
- Capsules are often enteric-coated to lower the chance of heartburn[1]
- A single 600 mg dose raised felodipine exposure to 140% of the water control[7]
- 4 graded human outcomes on this page
- October 12, 2026
How it works
ProposedPeppermint oil has antispasmodic properties, relaxing gut smooth muscle, which is the proposed basis for easing IBS pain. Menthol and menthyl acetate also inhibit the drug-metabolizing enzyme CYP3A4 in human liver microsomes.[5][7]
What the human research says
Human trials only, one row per outcome. The form column shows what each trial actually tested. Grades follow our evidence-grading policy.
| Outcome | Effect | Grade | Best evidence | PMID |
|---|---|---|---|---|
| Global IBS symptoms and abdominal pain | Improved | Grade B | Meta-analysis · n = 1,030 · 2022 Adults with IBS in 10 randomized trials Form: Peppermint oil capsules (mostly enteric-coated) · Dose: Varied across trials · Duration: Varied Fewer patients failed to improve on peppermint oil than placebo for global symptoms (RR 0.65, NNT 4) and abdominal pain (RR 0.76, NNT 7). Adverse events were more frequent (RR 1.57). Evidence quality was very low. | 35942669 (opens PubMed)Source [5] |
| Persistent IBS symptoms | Improved | Grade B | Meta-analysis · n = 392 · 2008 Adults with IBS in 4 placebo-controlled trials Form: Peppermint oil · Dose: Varied across trials · Duration: At least 1 week Persistent symptoms were less likely with peppermint oil than placebo (RR 0.43, 95% CI 0.32–0.59). | 19008265 (opens PubMed)Source [3] |
| Abdominal pain response and overall relief (primary endpoints) | No effect | Grade B | RCT · n = 189 · 2020 Adults with IBS (Rome IV) in the Netherlands Form: Small-intestinal-release or ileocolonic-release peppermint oil · Dose: 182 mg (dosing frequency not stated in the abstract) · Duration: 8 weeks Neither formulation beat placebo on the FDA pain-response endpoint (46.8% and 41.3% vs 34.4%) or the EMA overall-relief endpoint. Small-intestinal release improved only secondary measures (pain, discomfort, IBS severity). Mild adverse events were more common. | 31470006 (opens PubMed)Source [2] |
| IBS severity score (IBS-SSS) | No effect | Grade C | RCT · n = 133 · 2021 US adults with moderate to severe IBS (Rome IV) Form: Enteric-coated peppermint oil · Dose: 180 mg three times daily · Duration: 6 weeks Both groups improved substantially (90.8 vs 100.3 points); no significant difference on the primary or any secondary outcome (P = 0.97). | 34319275 (opens PubMed)Source [4] |
Forms
| Form | Elemental % | Absorption (human data) | GI tolerance | Studied for |
|---|---|---|---|---|
| Enteric-coated capsules (small-intestinal release) | Varies[2][4] | Coating delays release past the stomach; a targeted ileocolonic version showed no added benefit in PERSUADE.[1][2] | Heartburn and indigestion are the common effects; coating aims to reduce them.[1][5] | IBS symptoms (180–182 mg per dose in recent trials) |
| Ileocolonic-release capsules | Varies[2] | Releases oil in the lower small bowel and colon.[2] | Mild adverse events more common than placebo.[2] | IBS; not superior to placebo and not supported for further development by the trial authors |
| Peppermint leaf and tea | Varies[1] | No human absorption data in our sources.[1] | Tea appears safe; long-term safety of large amounts of leaf is unknown.[1] | Very little research on leaf for any condition |
| Topical oil, gel or cream | Varies[1] | Applied to skin, not swallowed.[1] | Skin rash and irritation; never on the face of infants or young children.[1] | Tension headache, nipple pain in breastfeeding (limited evidence) |
Studied doses
Doses studied in human trials ranged from 182 mg of peppermint oil per dose (dosing frequency not stated in the abstract) for 8 weeks to 180 mg of enteric-coated oil three times daily for 6 weeks.[2][4]
Interactions
Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.
Medicines
- Felodipine and other CYP3A4 substratesPK studyIn 12 healthy volunteers, a single 600 mg dose of peppermint oil raised felodipine exposure (AUC) to 140% of the water control; peppermint oil constituents inhibited CYP3A4 in liver microsomes.[7]
Who should be careful
- Heartburn or reflux
- Heartburn is a common side effect, and peppermint oil alone may worsen indigestion in some people.[1]
- Infants and young children
- Peppermint oil should not be applied to the face of infants or young children, because inhaled menthol may affect breathing.[1]
Talk to your pharmacist or clinician before starting a supplement, especially if you take prescription medicines.
Safety
Generally safe at common doses; heartburn is the main trade-off.
- Common side effects
- Heartburn, nausea, abdominal pain and dry mouth; rare allergic reactions.[1]
- More side effects than placebo
- Pooled trials found adverse events 1.57 times as common as with placebo, mostly mild reflux and indigestion.[5][1]
- Large doses
- Large doses can cause heartburn, nausea and vomiting.[6]
- Skin
- Topical use can cause rashes and irritation.[1]
How to read the label
- Label dose vs clinical doseRecent IBS trials used about 180 mg of oil per capsule, up to three times daily (540 mg/day). Check that the label states milligrams of peppermint oil and an enteric coating, not leaf powder.[2][4][1]
- Coating matters for comfortEnteric coating is used to lower heartburn risk; a targeted ileocolonic release gave no extra benefit.[1][2]
- Expect a strong placebo responseIn the 2021 US trial, placebo improved IBS scores as much as peppermint oil.[4]
Frequently asked questions
Does peppermint oil help IBS?
Meta-analyses find it better than placebo for overall symptoms and pain, but the evidence quality is very low and the two most rigorous recent trials missed their primary endpoints.[5][2][4]
What dose was used?
Recent trials used about 180 mg of peppermint oil per capsule, up to three times daily, for 6–8 weeks.[2][4]
Why enteric-coated?
Coating delays release past the stomach and is used to reduce the chance of heartburn, the most common side effect.[1]
Does peppermint oil interact with medicines?
A single 600 mg dose increased felodipine exposure by about 40%, possibly by inhibiting CYP3A4, so drugs cleared this way could be affected.[7]
Is peppermint oil safe for children?
It should not be applied to the face of infants or young children, because inhaled menthol may affect breathing.[1]
Sources
- [1]Peppermint Oil: Usefulness and Safety. NCCIH, 2025. fact-sheet
- [2]Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.. Gastroenterology, 2020. RCT
- [3]Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.. BMJ, 2008. meta-analysis
- [4]Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial.. Am J Gastroenterol, 2021. RCT
- [5]Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.. Aliment Pharmacol Ther, 2022. meta-analysis
- [6]Peppermint. Drugs and Lactation Database (LactMed).. NICHD, 2025. database
- [7]Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo.. Clin Pharmacol Ther, 2002. PK-study
- [8]Irritable Bowel Syndrome and Complementary Health Approaches: What the Science Says (accessed 2026-10-12). NCCIH, 2026. fact-sheet
What changed
- First draft (rebuilt after a lost earlier draft). Every PMID checked against NCBI E-utilities esummary (title and year) and the cited abstracts read. CommentsCorrections check: the 2008 BMJ meta-analysis (PMID 19008265) has a published erratum (BMJ 2009;338:b1881); PERSUADE (PMID 31470006) and the other cited PMIDs have none. No product links.
- Independent adversarial review (PR #201): spot-checked both meta-analyses, PERSUADE, the 2021 US trial and the felodipine study against PubMed abstracts. Summary and insight no longer call the positive pooled data 'older' (the 2022 meta-analysis is recent); felodipine mechanism stated as possible, as the authors did; microsome wording corrected; nipple-use line attributed to LactMed.